PharmaEngine Announces U.S. FDA Approves Merrimack's ONIVYDE(TM) (irinotecan liposome injection)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. SPGI
6. RIVN
7. LMT
8. RXST
9. AGIO
10. SPY

Go back to PharmaEngine Announces U.S. FDA Approves Merrimack's ONIVYDE(TM) (irinotecan liposome injection)

Merrimack Pharmaceuticals (MACK) PT Raised to $15 at Oppenheimer

October 27, 2015 8:17 AM EDT

Oppenheimer analyst Ling Wang reiterated an Outperform rating and boosted her price target on Merrimack Pharmaceuticals (NASDAQ: MACK) to $15.00 (from $13.00) after the FDA approved Onivyde (irinotecan liposome injection, or MM-398) in combination with fluorouracil (5-FU) and leucovorin (5-FU/LV) for the treatment of metastatic pancreatic... More